Zenas Biopharma's Purchased 60,000: Insider Buy Deep Dive
A biotech CEO just bought a sizable chunk of his company’s stock. That move sparks questions about conviction, risk, ...
If you ask why you keep overspending, you're not alone. This section breaks down frequent triggers and offers concrete fixes to align spending with goals.
22,840 articlesA biotech CEO just bought a sizable chunk of his company’s stock. That move sparks questions about conviction, risk, ...
Inflation has squeezed most Americans, but American Express remains focused on the affluent. This article examines wh...
Ripple’s XRP Ledger weighs a novel fix to curb front-running by bots. A proposal from David Schwartz could reserve tr...
A real-world look at why undisclosed stock trades in crypto can erode trust. This article uses a hypothetical scenari...
Meta Platforms is nudging into cloud computing, aiming to monetize idle compute and AI-ready infrastructure. This art...
A seasoned Wall Street investor reveals a sizable bet on Avalanche, arguing the platform’s treasury mechanics and sca...
A major energy partnership could reshape Chevron's cash flow and the stock's appeal before 2027. This guide breaks do...
Mitsubishi closed a $7.5 billion acquisition of Aethon Energy's U.S. gas assets, creating Adamas Energy in Dallas. Th...
Beaten-down brands aren’t a bet on luck—they’re a test of resilience. This piece explores two stocks down right hold ...
When insiders move shares, investors want to know why. This comprehensive guide breaks down why the electronic arts p...
Crypto hedge funds started 2026 with losses as volatility rose, prompting a shift to market-neutral and relative-valu...
Rhythmic secures a $4 million seed round led by Dragonfly to embed stablecoins into consumer-brand ecosystems, pairin...